News / Taiwan / economic_daily
PharmaEssentia Reports Triple-Digit Profit Growth, Eyes 2027 Expansion with Dual-Engine Strategy
Health Technology · Biotechnology · economic_daily · 2026-11-09
6446
PharmaEssentia posted a 113% surge in net profit for the first three quarters, driven by strong Ropeg sales and the expansion of new indications in global markets.
What Happened
Strong Financial Performance: PharmaEssentia reported a net profit of NT$7.602 billion for the first nine months of the year, marking a 113% increase compared to the same period last year. With an EPS of NT$18.43 and a gross margin of 93.6%, the company continues to demonstrate robust profitability as its flagship drug, Ropeg, scales globally.
Growth Drivers: October revenue hit a record high of NT$2.84 billion, representing a 102% year-over-year growth, bolstered by strong sales in the U.S. PV market and the introduction of a new injection pen. The launch of the ET indication in major markets like the U.S. and Japan is expected to be a primary revenue catalyst for Q4 and beyond.
Global Expansion: The company is aggressively expanding its footprint in the Asia-Pacific region, with its Australian subsidiary initiating regulatory filings and clinical partnerships. With ET approvals secured in multiple countries and pending in Singapore, PharmaEssentia is successfully transitioning toward a multi-market, multi-indication business model.
Clinical Advancements: Recent studies indicate that Ropeg has the potential to influence disease-related abnormal cells, supporting its role in disease-modifying therapies. Analysts view the commercial success of the ET indication as a critical metric for evaluating the company's growth trajectory toward 2027.